Brief: Aprea Therapeutics Announces Additional Positive Clinical Activity For Wee1 Inhibitor, APR-1051
18/02/2026 14:06
Feb 18 (Reuters) - Aprea Therapeutics Inc APRE.O: APREA THERAPEUTICS ANNOUNCES ADDITIONAL POSITIVE CLINICAL ACTIVITY FOR WEE1 INHIBITOR, APR-1051, INCLUDING SECOND PARTIAL RESPONSE IN ONGOING ACESOT-1051 TRIAL APREA THERAPEUTICS INC - TUMOR SHRINKAGE OF 50% AND SIGNIFICANT CA-125 BIOMARKER REDUCTION OBSERVED AT 220 MG DOSE LEVEL APREA THERAPEUTICS INC - UPDATE FROM TRIAL IS EXPECTED IN Q2 OF 2026 Source text: ID:nGNX9NWpJK Further company coverage: APRE.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Aprea Therapeutics
See all newsAprea Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Aprea Therapeutics Q2 net loss widens on higher R&D costs
Aprea Therapeutics Inc expected to post a loss of 23 cents a share - Earnings Preview
Brief: Aprea Therapeutics Provides Acesot-1051 Program Update For Wee1 Inhibitor Apr-1051 Accelerating And Expanding Enrollment. Clinical Data Presentation Planned For Q4 2026
Brief: Aprea Therapeutics - Files For Resale Of Up To 5.5 Million Shares By Selling Stockholders - SEC Filing